GLPG 1837

Drug Profile

GLPG 1837

Alternative Names: ABBV 974; GLPG1837

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics; Galapagos NV
  • Developer Galapagos NV
  • Class
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis

Most Recent Events

  • 20 Dec 2016 Efficacy and safety data from the phase II SAPHIRE-1 trial in cystic fibrosis released by Galapagos
  • 01 Nov 2016 Galapagos completes the phase II SAPHIRA-1 trial for Cystic fibrosis in Australia, Czech Republic, Germany, Ireland, United Kingdom (PO) (NCT02707562; EudraCT2015-003291-77)
  • 01 Sep 2016 Galapagos NV completes the SAPHIRA 2 phase II trial for Cystic fibrosis in Belgium and Netherlands (NCT02690519)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top